New research from Kaiser Permanente that followed a large number of people living with HIV over 15 years finds reduced risk of certain cancers is among the benefits of early treatment.
The Division of Research has joined a phase 3 clinical trial testing a Pfizer/BioNTech vaccine against the COVID-19 virus. Kaiser Permanente Southern California and Northwest join them in this global effort.
Kaiser Permanente’s rich history of research and care delivery innovation around HIV and AIDS will be highlighted at the global International AIDS Conference, being held online July 6-10.
Patients reported positive outcomes with use of an HIV prevention medication dosed only as needed, instead of the more common daily dosing, Kaiser Permanente researchers reported.
A JAMA study, using data on patients hospitalized in March from all 21 Kaiser Permanente Northern California hospitals, is one of the first U.S. studies to look at overall hospitalization admissions of COVID-19 patients.
A Kaiser Permanente study of women who were given inactivated influenza vaccine while pregnant found no indication of developmental problems for their babies at 6 months old.
Women who had an untreated infection during pregnancy were more likely to have a child who later went on to be obese than pregnant women who never had an infection, new research from Kaiser Permanente finds.
Black patients being treated for hepatitis C can take 8 weeks of certain direct-acting antiviral drugs rather than the previous recommendation of 12 weeks, updated guidelines say.
Kaiser Permanente researchers have developed a new analytical tool that identifies people at risk of contracting HIV so they may be referred for preventive medication.
A single, 45-minute “motivational interview” with two 20-minute follow-up phone calls may help people with HIV who report unhealthy drinking reduce their alcohol intake, say researchers at UC San Francisco and Kaiser Permanente.